

Thyroid cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/T756BACBB0EEN.html>

Date: May 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: T756BACBB0EEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Thyroid cancer - Pipeline Insight, 2021," report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Thyroid cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Thyroid cancer Understanding

Thyroid cancer: Overview

Thyroid cancer is a disease in which malignant (cancer) cells form in the tissues of the thyroid gland. Thyroid nodules are common but usually are not cancer. There are different types of thyroid cancer. Age, gender, and being exposed to radiation can affect the risk of thyroid cancer. Medullary thyroid cancer is sometimes caused by a change in a gene that is passed from parent to child. Signs of thyroid cancer include a swelling or lump in the neck. Tests that examine the thyroid, neck, and blood are used to diagnose thyroid cancer. Certain factors affect prognosis (chance of recovery) and treatment options.

'Thyroid cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Thyroid cancer pipeline landscape is provided which includes the disease overview and Thyroid cancer treatment guidelines. The assessment part of the report embraces, in depth Thyroid cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Thyroid cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Thyroid cancer R&D. The therapies under development are focused on novel approaches to treat/improve Thyroid cancer.

Thyroid cancer Emerging Drugs Chapters

This segment of the Thyroid cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Thyroid cancer Emerging Drugs

Donafenib: Suzhou Zelgen Biopharmaceuticals

Donafenib, an orally administered multikinase inhibitor, is being developed by Suzhou Zelgen Biopharmaceuticals for the treatment of Late stage cancers. The product targets Raf kinase and various receptor tyrosine kinases (RTKs), with potential antineoplastic activity. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.

Anlotinib: Jiangsu Chia-Tai Tianqing Pharmaceutical

Anlotinib is an orally administered tyrosine kinase inhibitor that targets vascular

endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Currently, it is in phase 3 of development stage for the treatment of thyroid cancer.

Ponatinib: Takeda

Ponatinib is an orally active, small-molecule multi-targeted tyrosine kinase inhibitor (TKI), being developed by Takeda, for the treatment of various cancer. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.

Nivolumab: Bristol-Myers Squibb

Nivolumab) is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. Currently, it is in phase 2 of development stage for the treatment of thyroid cancer.

Further product details are provided in the report..

Thyroid cancer: Therapeutic Assessment

This segment of the report provides insights about the different Thyroid cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Thyroid cancer

There are approx. 35+ key companies which are developing the therapies for Thyroid cancer. The companies which have their Thyroid cancer drug candidates in the most advanced stage, i.e. phase III include, Suzhou Zelgen Biopharmaceuticals.

Phases

DelveInsight's report covers around 35+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Thyroid cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Thyroid cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Thyroid cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Thyroid cancer drugs.

Thyroid cancer Report Insights

Thyroid cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Thyroid cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Thyroid cancer drugs?

How many Thyroid cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Thyroid cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Thyroid cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Thyroid cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Suzhou Zelgen Biopharmaceuticals

Jiangsu Chia-Tai Tianqing Pharmaceutical

Takeda

Bristol-Myers Squibb

Genentech

AffyImmune Therapeutics, Inc.

Taizhou Hanzhong biomedical co. LTD

NantCell, Inc.

Bayer

Merck Sharp & Dohme Corp.

Pfizer

MedImmune LLC

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Eisai Inc.

cCAM Biotherapeutics

Purple Biotech Ltd.

Turning Point Therapeutics, Inc.

Hoffmann-La Roche

Bicara Therapeutics

Novartis

GlobelImmune

GE Healthcare

IBC Pharmaceuticals

Debiopharm

Blueprint Medicines

Ono Pharmaceutical

Array BioPharma

Hutchison MediPharma

Celldex Therapeutics Inc

VBL Therapeutics

Biovista

Key Products

Donafenib

Anlotinib

Ponatinib

Nivolumab

Atezolizumab

AIC100

HX008

GI-6207

Ipilimumab

Regorafenib

MLN0128

Pembrolizumab

SU011248

Durvalumab

HA121-28

Ifosfamide

CM-24

ETBX-011

TPX-0046

Entrectinib

BCA101

Spartalizumab

GI 6207

EMI 137

Abemaciclib

DEBIO 1124

Gavreto

Encorafenib

Binimetinib

Surufatinib

CDX-3379

VB-111

BVA 701

Contents

Introduction

Executive Summary

Thyroid cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Thyroid cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Thyroid cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends

Thyroid cancer Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Donafenib: Suzhou Zelgen Biopharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Mid Stage Products (Phase II)

Comparative Analysis

Ponatinib: Takeda

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report..

Early Stage Products (Phase I)

- Comparative Analysis

AIC100: AffyImmune Therapeutics

- Product Description

- Research and Development

- Product Development Activities

Drug profiles in the detailed report..

Inactive Products

- Comparative Analysis

Thyroid cancer Key Companies

Thyroid cancer Key Products

Thyroid cancer- Unmet Needs

Thyroid cancer- Market Drivers and Barriers

Thyroid cancer- Future Perspectives and Conclusion

Thyroid cancer Analyst Views

Thyroid cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Thyroid cancer
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Thyroid cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Thyroid cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T756BACBB0EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T756BACBB0EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970